REMODULIN (TREPROSTINIL) INJECTION

Serial Number 77352192
Registration 3883260
800

Registration Progress

Application Filed
Dec 14, 2007
Under Examination
Aug 19, 2008
Approved for Publication
May 7, 2008
Published for Opposition
May 27, 2008
Registered
Nov 30, 2010

Trademark Image

REMODULIN (TREPROSTINIL) INJECTION

Basic Information

Serial Number
77352192
Registration Number
3883260
Filing Date
December 14, 2007
Registration Date
November 30, 2010
Published for Opposition
May 27, 2008
Renewal Date
November 30, 2020
Drawing Code
3000

Status Summary

Current Status
Active
Status Code
800
Status Date
Feb 28, 2021
Registration
Registered
Classes
005

Rights Holder

United Therapeutics Corporation

03
Address
1040 Spring Street
Silver Spring, MD 20910

Ownership History

United Therapeutics Corporation

Original Applicant
03
Silver Spring, MD

United Therapeutics Corporation

Owner at Publication
03
Silver Spring, MD

United Therapeutics Corporation

Original Registrant
03
Silver Spring, MD

Legal Representation

Attorney
Norm J. Rich

USPTO Deadlines

Next Deadline
1969 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2010-11-30)
Due Date
November 30, 2030
Grace Period Ends
May 30, 2031

Application History

50 events
Date Code Type Description
Feb 28, 2021 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 28, 2021 89AG O REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Feb 28, 2021 RNL1 Q REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Feb 28, 2021 NA89 E NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Nov 17, 2020 E89R I TEAS SECTION 8 & 9 RECEIVED
Nov 30, 2019 REM2 E COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Dec 19, 2016 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 19, 2016 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Dec 19, 2016 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Oct 11, 2016 E815 I TEAS SECTION 8 & 15 RECEIVED
Nov 30, 2010 R.PR A REGISTERED-PRINCIPAL REGISTER
Oct 26, 2010 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Oct 23, 2010 REGV O LAW OFFICE REGISTRATION REVIEW COMPLETED
Oct 22, 2010 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 20, 2010 DMCC I DATA MODIFICATION COMPLETED
Sep 27, 2010 SNEA W SU-EXAMINER'S AMENDMENT WRITTEN
Sep 27, 2010 GNEA O EXAMINERS AMENDMENT E-MAILED
Sep 27, 2010 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 27, 2010 XAEC I EXAMINER'S AMENDMENT ENTERED
Sep 21, 2010 CNRT W SU - NON-FINAL ACTION - WRITTEN
Sep 21, 2010 GNRT O NON-FINAL ACTION E-MAILED
Sep 21, 2010 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 1, 2010 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 31, 2010 EX4G S SOU EXTENSION 4 GRANTED
Aug 31, 2010 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Aug 17, 2010 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 17, 2010 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 17, 2010 EISU I TEAS STATEMENT OF USE RECEIVED
Aug 17, 2010 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 17, 2010 EXT4 S SOU EXTENSION 4 FILED
Aug 17, 2010 IUAF S USE AMENDMENT FILED
Feb 15, 2010 EX3G S SOU EXTENSION 3 GRANTED
Feb 12, 2010 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 12, 2010 EXT3 S SOU EXTENSION 3 FILED
Aug 13, 2009 EX2G S SOU EXTENSION 2 GRANTED
Aug 5, 2009 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 5, 2009 EXT2 S SOU EXTENSION 2 FILED
Feb 23, 2009 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 23, 2009 EX1G S SOU EXTENSION 1 GRANTED
Feb 9, 2009 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 9, 2009 EXT1 S SOU EXTENSION 1 FILED
Aug 19, 2008 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT
May 27, 2008 PUBO A PUBLISHED FOR OPPOSITION
May 7, 2008 NPUB O NOTICE OF PUBLICATION
Apr 21, 2008 ALIE A ASSIGNED TO LIE
Apr 21, 2008 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 16, 2008 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2008 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 1, 2008 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 1, 2008 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED

Detailed Classifications

Class 005
Cardiovascular pharmaceuticals
First Use Anywhere: 20100300
First Use in Commerce: 20100300

Additional Information

Design Mark
The mark consists of the word "REMODULIN" with two swooshes over the top and the words "(treprostinil) injection" underneath.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"(TREPROSTINIL) INJECTION"